Safety Study of Dantrolene in Subarachnoid Hemorrhage

Status Completed

Clinical Trial Summary

Subarachnoid hemorrhage (SAH) is a devastating acute brain injury due to bleeding onto the brain surface from a ruptured aneurysm. Cerebral vasospasm (cVSP; critical narrowing of brain arteries) is a known complication after SAH and significantly increases disability and death after SAH. Vasospasm is difficult to treat and can lead to stroke. Animal studies have shown that the muscles in the artery wall play a role in cVSP.

Dantrolene has been FDA approved and extensively used in clinical practice as a muscle relaxant for more than 30 years. It has been shown to provide some benefit in animal studies of cVSP, as well as in a small number of humans. However, the first human studies have only been observational and over a short period of time.

This study will evaluate the safety and tolerability of intravenous dantrolene given every 6 hours over seven days to patients with or at risk for cVSP after SAH. The goal is to determine if future efficacy studies should be done to determine if treatment with Dantrolene may improve the outcome of patients with cVSP after SAH.

Clinical Trial Description

Once eligibility criteria are met, patients will be randomized to either dantrolene-IV or placebo (equiosmolar, volume-equivalent sterile water with 5% mannitol as dantrolene-IV also contains 5% mannitol). Study subjects will be visited daily by a study nurse to determine side effects, tolerability, record hemodynamic measures and laboratory values. Patients will have daily serum Na, osmolality, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALK) measured. In addition, daily bedside transcranial doppler will be performed by a blinded examiner. Patients will undergo cerebral angiograms per clinical routine. Angiographic measurements of arterial narrowing will be performed by a blinded radiologist. Specific stop criteria are pre-defined. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01024972
Study type	Interventional
Source	University of Massachusetts, Worcester
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	October 2009
Completion date	October 2013

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06043167` - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Recruiting	`NCT04189471` - Recovery After Cerebral Hemorrhage
Completed	`NCT03281590` - Stroke and Cerebrovascular Diseases Registry
Completed	`NCT05131295` - Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.	Phase 3
Recruiting	`NCT02962349` - TRansfusion Strategies in Acute Brain INjured Patients	N/A
Completed	`NCT02872857` - Subarachnoid Hemorrhage Recovery And Galantamine	Phase 1/Phase 2
Terminated	`NCT02216513` - Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage	Phase 0
Completed	`NCT03164434` - Influence of Drainage on EVD ICP-signal
Completed	`NCT02389634` - Identification of Novel Molecular Markers for Vasospasm
Completed	`NCT01077206` - High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage	Phase 2/Phase 3
Not yet recruiting	`NCT00905931` - Lycopene Following Aneurysmal Subarachnoid Haemorrhage	Phase 2
Completed	`NCT00962546` - Computed Tomographic (CT) Perfusion and CT Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage	N/A
Completed	`NCT01261091` - Early Tracheostomy in Ventilated Stroke Patients	N/A
Completed	`NCT00507104` - Pituitary Functions After Traumatic Brain Injury (TBI) and/or Subarachnoid Hemorrhage (SAH)
Completed	`NCT00071565` - Familial Intracranial Aneurysm Study II	N/A
Recruiting	`NCT05113381` - The Purpose of This Study is to Determine Whether CerebroFlo™ EVD Catheter is Effective During the Treatment of IVH	N/A
Completed	`NCT04052646` - Prehospital Deaths From Spontaneous Subarachnoid Haemorrhages
Recruiting	`NCT04548596` - NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Recruiting	`NCT06033378` - Blood Pressure Treatment in ICU Patients With Subarachniodal Haemorrhage.	N/A
Completed	`NCT04308577` - Diet Induced Ketosis for Brain Injury - A Feasibility Study	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.